Insights+: Key Deals of JP Morgan Healthcare Conference 2021
Shots: The approval is based on P-lll COAST-X study assessing Taltz (80mg, q4w) vs PBO for the treatment of adult patients with nr-axSpA with objective signs of inflammation for 52wks. Result: 1EPs of ASAS40 @16wks. (35% vs 19%); ASAS40 response @52wks. (30% vs 13%), met its 2EPs, showing efficacy in reducing disease activity and sacroiliac […]Read More